Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 10

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 10
---
 Securities and Exchange Commission, Swiss Takeover Board, the Israel Securities Authority or any state securities commission has approved or disapproved the Merger described in this proxy statement/prospectus or the NLS Common Shares to be issued in connection with the Merger or passed upon the adequacy or accuracy of this proxy statement/prospectus. Any representation to the contrary is a criminal offense. This proxy statement/prospectus is not intended to be and is not a prospectus for purposes of the Israeli Securities Law, 5728-1968, and the Israeli Securities Authority has not approved this proxy statement/prospectus. The accompanying proxy statement is dated July 18, 2025, and is first being mailed to NLS shareholders on or about July 31, 2025.

PRELIMINARY PROXY STATEMENT, SUBJECT TO COMPLETION NLS PHARMACEUTICS LTD.
The Circle 6
8058 Zurich, Switzerland
Tel: +41.44.512.2150 NOTICE OF EXTRAORDINARY MEETING OF SHAREHOLDERS
TO BE HELD ON AUGUST 21, 2025 To the shareholders of NLS Pharmaceutics Ltd., Zurich, Switzerland Zurich, July 18, 2025 Invitation to the Extraordinary Shareholders’ Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Dear Shareholder, The board of directors of NLS Pharmaceutics Ltd. (the “Board of Directors”), with registered office at The Circle6, 8058 Zurich, Switzerland (the “Company”), is pleased to invite you to the extraordinary shareholders’ meeting of the Company (the “NLS Meeting”). The shareholders’ meeting will be held as follows:

| Date:         |     | August 21, 2025                                                                                |
|:--------------|:----|:-----------------------------------------------------------------------------------------------|
| Doors open:   |     | 3:45 pm (CET)                                                                                  |
| Meeting time: |     | 4:00 pm (CET)                                                                                  |
| Place:        |     | At the premises of Baker McKenzie Switzerland AG, Holbeinstrasse 30, 8034 Zurich, Switzerland. |

The agenda items to be voted on, the voting instructions and the appendices mentioned herein are provided below: The Board of Directors reserves the right, for important reasons in the interest of the Company, to withdraw all subsequent proposals should any agenda item be rejected by the shareholders. In this case, none of the agenda items would be put to a vote. The agenda